News

A look at vital figures makes it clear that Vetter is a very successful, globally active Contract Development and Manufacturing Organization (CDMO). Over the last ten years, the company has more than doubled its annual sales revenues to approximately...

GlaxoSmithKline and Samsung Biologics have entered into a partnership to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies. Under the terms of the agreement, Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical...

Roche announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size...

Novavax, Inc. , a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX CoV2373, a stable, prefusion protein made using...

Thermo Fisher Scientific, the world leader in serving science, and Biognosys, a leading developer of next-generation proteomics solutions, announce they are continuing their collaboration to advance data independent acquisition (DIA) mass spectrometry-based workflows. Together, the companies have developed a...

Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate for SARS-CoV-2. Themis has a pipeline of vaccine candidates and immune modulatory therapies developed using its...

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the companies have entered into a collaboration agreement to develop EIDD-2801, an orally available antiviral candidate currently in...